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Abstract
Background: A meta-analysis found that high dose vitamin D, different from low dose, decreased
fracture risk by 23% for any nonvertebral fracture and by 26% for hip fracture. Unfortunately,
however, this effect was not confirmed by recent trials. The aim of this paper is to explore if this
inconsistency can be attributed to publication bias or heterogeneity of the trials.
Methods: The meta-analysis was extended with recent randomised controlled trials (RCTs) that
were identified by a systematic review. Risk ratios (RR) and 95% confidence intervals (CI) were
calculated from raw data. A funnel plot was used to explore the possibility of publication bias.
Forest plots were used to investigate if vitamin D dose, concurrent use of calcium and target
population were sources of heterogeneity. Linear regression analysis of log RR on adherence rate
and achieved vitamin D level was used to study whether these variables were associated with
fracture risk.
Results: A total of eleven trials was included: seven RCTs from the meta-analysis and four recently
published. For any nonvertebral fracture, the funnel plot was asymmetrical because two small RCTs
showed a large positive effect. This was not found for hip fracture. As reported in the meta-analysis,
low dose vitamin D (<400 IU daily) was not effective. In contrast to the meta-analysis, however,
the effect of high dose vitamin D (≥700 IU daily) seemed to be dependent on target population. For
any nonvertebral fracture, the pooled RR was 0.80 (95% CI, 0.70–0.90) in institutionalised persons,
and 0.88 (95% CI, 0.75–1.04) in the general population; for hip fracture, pooled RR 0.72 (95% CI,
0.59 to 0.88) and 1.04 (95% CI, 0.72–1.50), respectively. Other sources of heterogeneity were not
clearly found. In the meta-analysis, pooled RRs were mainly based on small trials that showed a
large effect or trials in institutionalised persons.
Conclusion: It is likely that the inconsistency between the meta-analysis and the recent trials is,
at least partially, due to publication bias and differences in target population. High dose vitamin D
may be effective in institutionalised persons but probably is not effective in the general population.
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Controversy persists whether low-trauma or osteoporotic
fractures can be prevented with vitamin D supplementa-
tion. In 2005, the divergent findings were addressed in a
meta-analysis and the results were hopeful [1]. Although
an oral vitamin D dose of 400 IU daily was not sufficient
for fracture prevention, fracture risk was reduced by 23 to
26 percent if vitamin D supplementation was given in a
daily dose of 700 to 800 IU. However, the positive effect
of high dose vitamin D supplementation was not con-
firmed in more recent trials and Cochrane reviewers also
came to a different conclusion [2-4]. Therefore, we must
question why the results are inconsistent. In general, pub-
lication bias of the meta-analysis of 2005 or heterogeneity
of the trials, for example due to differences in target pop-
ulation or adherence rate, are likely explanations. The aim
of this paper is to investigate which of these factors may
play a role.
Methods
I performed a systematic review of the literature using
MEDLINE (PubMed) to identify randomised controlled
trials (RCTs) on fracture prevention with vitamin D sup-
plementation that were published after the meta-analysis
of 2005. "Cholecalciferol", "ergocalciferol", "25-hydroxy-
vitamin D 2", "vitamin D", "fracture" and "fall" were used
as search terms (Medical Subject Heading (MeSH) and
text word) and the search was limited to randomised con-
trolled trials with publication date January 1, 2005 or
later. Furthermore, I checked the ongoing trials described
in the Cochrane review [4]. As a next step, I applied the
same criteria for eligibility as was done in the meta-analy-
sis [1]. A trial was included if it was a double-blind RCT
that studied oral vitamin D supplementation (cholecalcif-
erol or ergocalciferol) with a minimum follow-up of one
year and if there was more than a total of one fracture in
the trial. Measurement of 25-hydroxyvitamin D levels
during follow-up was not required because it would lead
to exclusion of two of the largest trials [2,5].
The raw data of all RCTs were entered in Review Manager
(RevMan) 4.2.6 [6]to calculate risk ratios (RR) and 95 per-
cent confidence intervals (CI), using a fixed effects model,
and to draw a funnel plot.
To study possible sources of heterogeneity, risk ratios are
presented according to target population (institutional-
ised persons, general population), vitamin D dose (low
dose, 400 IU daily; high dose, ≥ 700 IU daily), and con-
current use of calcium supplements (no, yes). In addition,
linear regression analysis of log RR on adherence rate,
achieved vitamin D level, age and absolute fracture risk
was carried out to study the influence of these variables on
fracture risk. This was done in SPSS 12.0.1 for Windows
(SPSS Inc, Chicago, Illinois, USA).
Results
Non-vertebral fractures
Eleven RCTs reported on the risk of any nonvertebral frac-
ture. Seven trials were included in the meta-analysis of
2005 [7-13], and four were published recently [2,3,5,14].
Two early RCTs showed a statistically significant decrease
of fracture risk in the treatment group (figure 1) [7,9]. One
RCT showed a decrease of fracture risk that was of border-
line statistical significance [13]. Eight RCTs did not show
a positive effect of vitamin D supplementation 2005
[2,3,5,8,10-12,14].
When a funnel plot is drawn, two RCTs clearly attract
attention (figure 2). These trials were relatively small but
showed the largest decrease of fracture risk in the treat-
ment group. The Dawson trial included 389 persons and
the Pfeifer trial 137 persons [9,10]. The risk ratios were
0.39 (95% CI, 0.20 to 0.77) and 0.48 (95% CI, 0.12 to
1.84), respectively. Both trials were included in the meta-
analysis of 2005. The other trials are evenly distributed
around the pooled risk ratio that is based on the data of
the eleven RCTs (RR 0.94; 95 percent CI, 0.89 to 0.98).
Publication bias, chance and hetereogeneity of the RCTs
are the main factors to explain the asymmetry of the fun-
nel plot. Heterogeneity may be due to differences in target
population, vitamin D dose, and concurrent use of cal-
cium supplements. Therefore, as a next step, forest plots
were drawn according to these possible sources of hetero-
geneity (figures 3A–D).
Low dose vitamin D supplementation (400 IU daily) did
not decrease fracture risk in any of the trials (figures 3A–
B). The effect of high dose vitamin D supplementation (≥
700 IU daily) was dependent on the target population. A
consistent decrease of fracture risk was seen in institution-
alised persons who took high dose vitamin D supplemen-
tation combined with extra calcium (600 to 1200 mg
daily) (figure 3C) although it must be recognised that two
of the three trials were performed by the same authors
[7,11]. The pooled risk ratio in the treatment group was
0.80 (95 percent CI, 0.70 to 0.90) in institutionalised per-
sons.
Four RCTs that used high dose vitamin D supplementa-
tion in combination with extra calcium (500 to 1200 mg
daily) were performed in the general population (figure
3D). Here, again, the Dawson and Pfeifer trial attract
attention. Although these small trials found a large
decrease of fracture risk, two recent large trials found no
effect. The pooled risk ratio in the treatment group was
0.88 (95% CI, 0.75 to 1.04) in the general population.
Most authors did not clearly describe their definition of
adherence to the trial medication nor the method byPage 2 of 8
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Risk ratio for any nonvertebral fracture in a comparison of vitamin D supplementation (treatment) with placeboF gu e 1
Risk ratio for any nonvertebral fracture in a comparison of vitamin D supplementation (treatment) with pla-
cebo. The trials are ordered according to year of publication. Bars represent 95 percent confidence intervals. Pooled risk 
ratio, 0.94 (95 percent confidence interval, 0.89 to 0.98).
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Funnel plot of randomised controlled trials on the prevention of any nonvertebral fracture with vitamin D supplementationigure 2
Funnel plot of randomised controlled trials on the prevention of any nonvertebral fracture with vitamin D sup-
plementation. Open symbols: trials included in the meta-analysis. Solid symbols: recent trials. Dashed line: pooled risk ratio 
(RR, 0.94; 95 percent confidence interval, 0.89 to 0.98).
BMC Musculoskeletal Disorders 2007, 8:26 http://www.biomedcentral.com/1471-2474/8/26which it was assessed. The reported adherence rates varied
between 55 and 95 percent. The correlation between
adherence and risk ratio was not statistically significant
nor was the slope of the regression line statistically signif-
icant different from zero (figure 4). Similar results were
found for the relation between risk ratio and achieved
vitamin D concentration (figure 5), age and absolute frac-
ture risk (data not shown).
Hip fractures
Data on hip fracture were reported in eight RCTs
[2,3,5,7,8,11-13]. Here also, the RCTs showed divergent
Risk ratios for any nonvertebral fracture according to target population, vitamin D dose and concurrent use of calciumF gu e 3
Risk ratios for any nonvertebral fracture according to target population, vitamin D dose and concurrent use of 
calcium. Bars represent 95 percent confidence intervals.Page 5 of 8
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included in the meta-analysis of 2005 and the recent
RCTs, and the funnel plot was symmetrical (data not
shown). No RCT showed a positive effect of low dose vita-
min D [5,8,12]. High dose vitamin D seemed to be effec-
tive in institutionalised persons (two trials; RR 0.72; 95
percent CI, 0.59 to 0.88) [7,11] but not in the general
population (two trials; RR 1.04; 95 percent CI, 0.72 to
1.50)[2,3].
Discussion
First of all, it must be said that the number of RCTs on
fracture prevention with vitamin D is too small for far
reaching conclusions. The funnel plot may be misleading
and the assessment of heterogeneity may be inadequate.
Nevertheless, some cautious conclusions can be drawn.
Low dose vitamin D was not effective in any trial. This was
also concluded by the authors of the meta-analysis of
2005. However, the effectiveness of high dose vitamin D
seems to be dependent on the target population. High
dose vitamin D lowered fracture risk by about 20 percent
in institutionalised persons but did not result in a statisti-
cally significant decrease in fracture risk in the general
population.
It is plausible that the effect of vitamin D supplementa-
tion in institutionalised persons is larger than in the gen-
eral population. As institutionalised persons are exposed
to sunlight less often than persons from the general pop-
ulation, it can be assumed that without supplementation
the vitamin D levels are lower in institutionalised persons.
Accordingly, it may be expected that supplementation has
Risk ratios for any nonvertebral fracture according to adherence to the trial medicationF gu e 4
Risk ratios for any nonvertebral fracture according to adherence to the trial medication. Slope: slope of the 
regression line. 95%CI: 95 percent confidence interval. Pearson correlation coefficient: -0.56 (p = 0.10).Page 6 of 8
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of vitamin D supplementation on fracture risk, we must
distinguish between institutionalised persons and per-
sons from the general population.
In the meta-analysis, ìt was estimated that high dose vita-
min D lowered the risk of any nonvertebral fracture by 23
percent. The estimate was based on the pooled results of
five RCTs [7,9-11,13]. Two of the trials were performed in
institutionalised persons and three in the general popula-
tion. As stated above, the effect of vitamin D may be larger
in institutionalised persons. By pooling the data from
institutionalised persons and the general population, the
meta-analysis probably overestimated the effect of vita-
min D supplementation.
Furthermore, two of the three trials in the general popula-
tion that were included in the meta-analysis were small
but showed a large positive effect [9,10]. As illustrated by
the asymmetry of the funnel plot, there were no small tri-
als with a negative effect. This may be due to publication
bias as publication bias is more likely to affect small rather
than large trials [15]. Obviously, the asymmetry of the
funnel plot also may be due to chance because the
number of included trials is small. However, apart from
the underlying mechanism, inclusion of the small studies
also may have led to overestimation of the effect of high
dose vitamin D in the meta-analysis.
Apart from vitamin D dose and target population, adher-
ence rate to the trial medication and achieved vitamin D
Risk ratios for any nonvertebral fracture according to achieved vitamin D levelF gu e 5
Risk ratios for any nonvertebral fracture according to achieved vitamin D level. Slope: slope of the regression line. 
95%CI: 95 percent confidence interval. Pearson correlation coefficient: -0.54 (p = 0.17). Multiply values by 0.40 to convert 25-
OH-vitamin D to ng/ml.Page 7 of 8
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concentration are often mentioned as possible sources of
heterogeneity. Bearing in mind its limitations, the present
analysis did not clearly show an association. Some might
argue that an association is suggested by the negative
slopes of the regression lines but this also seems in large
part due to the small Dawson and Pfeifer trials. Naturally,
it may be mentioned that the effect in the Dawson trial
was large precisely because the adherence rate and the
achieved vitamin D level were high but studies with simi-
lar adherence rates or vitamin D levels did not show such
large effects.
Conclusion
It is likely that the inconsistency between the meta-analy-
sis and the recent trials is, at least partially, due to publi-
cation bias and differences in target population. High
dose vitamin D may be effective in institutionalised per-
sons but probably is not effective in the general popula-
tion.
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